The point company has not been onto PR has made it difficult for continuous SP rise. Last quarterly should have news of AU enteric site open, FDA application, new partner overseas and winter flu testing sales, due in 2 weeks time. Both FY22 report and FY23 outlook should be bright and take SP upwards from here.
The point company has not been onto PR has made it difficult for...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
67.5¢ |
Change
0.005(0.75%) |
Mkt cap ! $153.1M | |||
| Open | High | Low | Value | Volume |
| 67.5¢ | 67.5¢ | 67.5¢ | $36.16K | 53.58K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 45052 | 67.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 68.0¢ | 189522 | 2 |
View Market Depth
| Last trade - 11.49am 27/09/2024 (20 minute delay) ? |
| GSS (ASX) Chart |